CME Statement and Objectives

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Vermont and the American Society for Experimental NeuroTherapeutics. The University of Vermont is accredited by the ACCME to provide continuing medical education for physicians.

The University of Vermont designates this educational activity for a maximum of 12.75 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should only claim those credits that he/she actually spent in the activity.

This Sixth Annual Meeting of ASENT presents two plenary symposia and three specialized workshops on topics of timely interest for investigators and other professionals interested in the broad field of neurotherapeutics. At the completion of the meeting, annual meeting participants will be able to:

• Understand the path of drug development from discovery to approval of a new interventional therapy, from developing an experimental neurotherapeutic trial, consent and clinical equipoise, and the regulatory perspectives involved in initiating clinical research.

• Evaluate the range of issues that clinical experimental neurotherapeutic research must address as they relate to placebos and active controls in clinical trials. Statistical issues, regulatory perspectives, and perspectives of the pharmaceutical industry on placebo and active controls in clinical trials will be reviewed.

• Assess the aspects of potential mechanisms of the placebo response and appreciate the subject’s perspective on trials with placebos.

• Evaluate the concept of translational neurotherapeutics and the approach to symptomatic intervention and biologic intervention from molecules, animal models, and human research.

• Discuss the developments in proteosomes and in the role in human disease as well as in neurotherapeutics.

• Discuss the new developments of potential therapies as learned from animal models of two neurodegenerative disorders, Parkinson’s and Alzheimer’s disease.

• Discuss the regulatory perspective of the use of bio-markers in translational research.

• Appreciate the complexity of privacy in clinical research. Specifically, understanding the key issues involved in the privacy of research specimens and the privacy of genetic information.

• Assess the potential of neuroimaging as an outcome measure in such disorders as Alzheimer’s disease, Stroke and Multiple Sclerosis.

• Review the recent clinical trials findings in such areas as Epilepsy, Alzheimer’s disease, and Malignant Glioma.